相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC
Jian Huang et al.
ONCOGENE (2020)
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
Riyaz Shah et al.
CLINICAL LUNG CANCER (2020)
Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays
Chia- Shen et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2020)
Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations
Xiao-Feng Li et al.
SCIENTIFIC REPORTS (2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper et al.
CELL REPORTS MEDICINE (2020)
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Quincy S. Chu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer
Li Li et al.
CANCER LETTERS (2019)
Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases
Halla Vidarsdottir et al.
HUMAN PATHOLOGY (2019)
Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines
Tianxiang Chen et al.
THORACIC CANCER (2019)
Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan
Hsiang-Ling Ho et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2019)
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
Yuxin Mu et al.
TARGETED ONCOLOGY (2019)
LC3-positive structures are prominent in autophagy-deficient cells
Gautam Runwal et al.
SCIENTIFIC REPORTS (2019)
Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy
Mau Ern Poh et al.
THORACIC CANCER (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment
Tianli Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
Yoojung Kwon et al.
CANCERS (2019)
Metformin-sensitized NSCLC cells to osimertinib via AMPK-dependent autophagy inhibition
Hengyi Chen et al.
CLINICAL RESPIRATORY JOURNAL (2019)
EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
Xuan Zhu et al.
FRONTIERS IN ONCOLOGY (2019)
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
Masayuki Takeda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harboring uncommon EGFR mutations: a case report and literature review
Taiki Hakozaki et al.
ONCOTARGETS AND THERAPY (2019)
Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution
Loukia G. Karacosta et al.
NATURE COMMUNICATIONS (2019)
Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma
Mohammad Jafarnejad et al.
NPJ SYSTEMS BIOLOGY AND APPLICATIONS (2019)
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer
Lixian Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling
Yanmei Yi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
Christina Demuth et al.
BMC CANCER (2018)
MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer
Ying Zhang et al.
MOLECULAR CANCER (2018)
The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
Hengrui Liang et al.
JOURNAL OF THORACIC DISEASE (2018)
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer
Tamkin Ahmadzada et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers
Min Pan et al.
PLOS BIOLOGY (2018)
A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group
Tao Jiang et al.
JOURNAL OF THORACIC DISEASE (2018)
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
Mau-Ern Poh et al.
JOURNAL OF THORACIC DISEASE (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
The epidemiology of lung cancer
Patricia M. de Groot et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
Ji Yeon Kim et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer Associated Fibroblast Interactions during Collective Invasion
Alessandra M. Richardson et al.
CLINICAL CANCER RESEARCH (2018)
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
Yuh-Min Chen
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evidence for circulating cancer stem-like cells and epithelial-mesenchymal transition phenotype in the pleurospheres derived from lung adenocarcinoma using liquid biopsy
Sheefa Mirza et al.
TUMOR BIOLOGY (2017)
Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations
Guanhua Rao et al.
SCIENTIFIC REPORTS (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Resisting Resistance: Targeted Therapies in Lung Cancer
Jessica J. Lin et al.
TRENDS IN CANCER (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
Novel steps in the autophagic-lysosomal pathway
Frank Saetre et al.
FEBS JOURNAL (2015)
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
Kang-Seo Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application
Xun Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells
Donglei Liu et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2014)
Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells
Donghai Jiang et al.
CANCER LETTERS (2013)
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer
Wen-Shuo Wu et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2013)
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
N. Girard et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer
Zhi-Yi Zhou et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2012)
Selective autophagy mediated by autophagic adapter proteins
Terje Johansen et al.
AUTOPHAGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Control of autophagy by oncogenes and tumor suppressor genes
M. C. Maiuri et al.
CELL DEATH AND DIFFERENTIATION (2009)
分享论文
